MCID: DBT004
MIFTS: 50

Diabetic Polyneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

MalaCards integrated aliases for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 12 54 15 32
Diabetes Mellitus with Polyneuropathy 12
Polyneuropathy in Diabetes 12
Diabetic Polyneuropathies 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12785
ICD9CM 34 357.2
MeSH 43 D003929
SNOMED-CT 67 49455004
ICD10 32 G63.2
UMLS 71 C0271680

Summaries for Diabetic Polyneuropathy

MalaCards based summary : Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to microvascular complications of diabetes 3 and polyneuropathy. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MAPK signaling pathway. The drugs Cilostazol and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Diabetic Polyneuropathy

Diseases related to Diabetic Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 30.2 INS AKR1B1 AGER
2 polyneuropathy 30.2 VEGFA TWNK TNF POLG NGF INS
3 osteonecrosis 30.1 VEGFA TNF NOS3
4 uremia 29.6 TNF NOS2 INS
5 neurogenic arthropathy 29.5 NGF INS
6 hyperglycemia 29.5 SOD2 NOS3 NOS2 INS APOB AKR1B1
7 coronary heart disease 1 29.4 NOS3 INS CYBA APOB
8 autonomic neuropathy 29.4 NTF3 NGF INS AKR1B1
9 microvascular complications of diabetes 5 29.4 VEGFA SOD2 NOS3 NOS2 INS AKR1B1
10 axonal neuropathy 29.3 TWNK SLC25A4 POLG
11 diabetic neuropathy 29.3 VEGFA SOD2 NTF3 NGF INS AKR1B1
12 sleep apnea 29.2 VEGFA TNF NOS3 INS APOB
13 impotence 29.1 NOS3 NOS2 NOS1 INS
14 sensory peripheral neuropathy 29.1 POLG NTF3 NGF AKR1B1
15 peripheral vascular disease 29.1 VEGFA NOS3 NOS2 INS APOB
16 diabetic autonomic neuropathy 29.0 NTF3 NGF INS AKR1B1
17 atherosclerosis susceptibility 28.9 VEGFA TNF NOS3 INS CYBA APOB
18 constipation 28.8 NTF3 NOS2 NOS1 AKR1B1
19 diabetes mellitus 28.4 VEGFA TNF SOD2 PARP1 NOS3 INS
20 diabetes mellitus, insulin-dependent 28.3 VEGFA TNF SOD2 NOS3 NOS2 INS
21 peripheral nervous system disease 28.2 VEGFA TWNK TNF POLG NTF3 NGF
22 vascular disease 28.2 VEGFA TNF NOS3 NOS2 NOS1 INS
23 neuroblastoma 27.5 VEGFA TNF SOD2 PARP1 NTF3 NGF
24 diabetes mellitus, noninsulin-dependent 27.4 VEGFA TNF SOD3 NOS3 NGF INS
25 alzheimer disease 26.1 VEGFA TNF SOD2 NTF3 NOS3 NOS2
26 neuropathy 10.7
27 hemifacial spasm 10.5 VEGFA NOS3
28 lymphangiosarcoma 10.4 VEGFA TNF
29 platelet membrane fluidity 10.4 NOS3 NOS2
30 radiation proctitis 10.4 VEGFA TNF
31 eclampsia 10.3 VEGFA TNF NOS3
32 ataxia neuropathy spectrum 10.3 TWNK POLG
33 leukostasis 10.3 VEGFA NOS3 AGER
34 hepatic vascular disease 10.3 VEGFA TNF NOS3
35 spotted fever rickettsiosis 10.3 TNF NOS2
36 polg-related disorders 10.3 TWNK POLG
37 soft tissue sarcoma 10.3 VEGFA TNF
38 carotid stenosis 10.3 VEGFA TNF NOS3
39 paresthesia 10.3
40 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 10.3 TWNK POLG
41 limb ischemia 10.3 VEGFA TNF NOS3
42 carpal tunnel syndrome 10.3
43 autonomic dysfunction 10.3
44 myotonic cataract 10.3 TWNK POLG
45 diabetic cataract 10.3 VEGFA NOS2 AKR1B1
46 diabetic macular edema 10.2 VEGFA SOD2 NOS3 AKR1B1
47 retroperitoneal hemangiopericytoma 10.2 VEGFA INS
48 diabetes mellitus, insulin-dependent, 23 10.2 TNF INS
49 eales disease 10.2 VEGFA TNF NOS2
50 female breast upper-inner quadrant cancer 10.2 NOS2 NOS1

Comorbidity relations with Diabetic Polyneuropathy via Phenotypic Disease Network (PDN): (show all 30)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Bronchitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Cataract
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Kidney Disease
Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 7
Mitral Valve Disease Mononeuritis Multiplex
Mononeuropathy of the Median Nerve, Mild Neurogenic Arthropathy
Neurogenic Bladder Partial Third-Nerve Palsy
Peripheral Vascular Disease Respiratory Failure
Tabes Dorsalis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to Diabetic Polyneuropathy

Symptoms & Phenotypes for Diabetic Polyneuropathy

GenomeRNAi Phenotypes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 AKR1B1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.91 NTF3 SLC25A4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.91 NTF3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.91 NTF3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.91 AKR1B1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 AKR1B1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.91 CYBA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.91 CYBA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.91 AKR1B1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.91 CYBA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.91 NTF3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 CYBA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.91 SLC25A4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 PARP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 PARP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.91 CYBA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.91 SLC25A4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.91 NTF3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 SLC25A4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.91 CYBA NTF3 PARP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.91 CYBA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.91 PARP1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.91 PARP1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 SLC25A4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.91 AKR1B1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.91 AKR1B1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.91 AKR1B1 CYBA NTF3 PARP1 SLC25A4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.91 SLC25A4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.91 PARP1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.91 AKR1B1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 NTF3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.91 SLC25A4

MGI Mouse Phenotypes related to Diabetic Polyneuropathy:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 AGER AKR1B1 APOB CYBA INS NGF
2 cardiovascular system MP:0005385 10.46 AGER APOB CYBA INS NGF NOS1
3 cellular MP:0005384 10.42 AGER APOB CYBA INS NOS1 NOS2
4 behavior/neurological MP:0005386 10.4 AGER AKR1B1 CYBA INS NGF NOS1
5 growth/size/body region MP:0005378 10.4 AGER AKR1B1 APOB INS NGF NOS1
6 mortality/aging MP:0010768 10.35 AKR1B1 APOB INS NGF NOS1 NOS2
7 immune system MP:0005387 10.34 AGER APOB CYBA INS NOS1 NOS2
8 hematopoietic system MP:0005397 10.29 AGER CYBA INS NOS1 NOS2 NOS3
9 muscle MP:0005369 10.27 AGER APOB INS NGF NOS1 NOS2
10 nervous system MP:0003631 10.25 APOB CYBA INS NGF NOS1 NOS2
11 adipose tissue MP:0005375 10.2 CYBA INS NOS1 NOS2 NOS3 POLG
12 digestive/alimentary MP:0005381 10.17 CYBA INS NOS1 NOS2 NOS3 POLG
13 integument MP:0010771 10.16 AGER INS NGF NOS2 PARP1 POLG
14 liver/biliary system MP:0005370 10.1 APOB INS NOS1 NOS2 NOS3 SOD2
15 normal MP:0002873 10.02 AGER INS NGF NOS1 NOS3 NTF3
16 no phenotypic analysis MP:0003012 10.01 INS NGF NOS1 PARP1 POLG SOD3
17 reproductive system MP:0005389 10 APOB INS NOS1 NOS2 NOS3 NTF3
18 renal/urinary system MP:0005367 9.97 AGER AKR1B1 INS NOS1 NOS2 NOS3
19 skeleton MP:0005390 9.73 AGER AKR1B1 CYBA INS NOS1 NOS2
20 respiratory system MP:0005388 9.7 CYBA NOS1 NOS2 NOS3 NTF3 TNF
21 vision/eye MP:0005391 9.44 AKR1B1 APOB CYBA INS NGF NOS1

Drugs & Therapeutics for Diabetic Polyneuropathy

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3 Immunologic Factors Phase 4
4 Immunoglobulins Phase 4
5 Antibodies Phase 4
6 Immunoglobulins, Intravenous Phase 4
7 Rho(D) Immune Globulin Phase 4
8 gamma-Globulins Phase 4
9 Fibrinolytic Agents Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Respiratory System Agents Phase 4
12 Platelet Aggregation Inhibitors Phase 4
13 Autonomic Agents Phase 4
14 Vasodilator Agents Phase 4
15 Neuroprotective Agents Phase 4
16 Bronchodilator Agents Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Phosphodiesterase 3 Inhibitors Phase 4
19 Dermatologic Agents Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Antirheumatic Agents Phase 4
24 Linoleate Phase 4
25 Evening Primrose Phase 4
26 Phosphodiesterase 5 Inhibitors Phase 4
27
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
28
Capsaicin Approved Phase 2, Phase 3 404-86-4 1548943
29
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
30
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
31
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
32
Tapentadol Approved Phase 3 175591-23-8 9838022
33
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 70-16-6, 59-43-8 1130
34
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
36
Cobalamin Experimental Phase 3 13408-78-1 6857388
37 Chelating Agents Phase 3
38 Adjuvants, Immunologic Phase 3
39 Benphothiamine Phase 3
40 Antipruritics Phase 2, Phase 3
41 Thiamin Phase 3
42 Vitamin B 12 Phase 3
43 Vitamin B12 Phase 3
44 Antimanic Agents Phase 3
45 Excitatory Amino Acid Antagonists Phase 3
46 Excitatory Amino Acids Phase 3
47 Adrenergic Agents Phase 3
48 Protective Agents Phase 3
49 Trace Elements Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
3 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
4 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
5 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
6 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
7 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
8 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
9 A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
10 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
11 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups Completed NCT00328601 Phase 3 Thioctic Acid
12 Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study Completed NCT01263132 Phase 3 F0434;Gabapentin
13 Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Completed NCT01465620 Phase 3
14 A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00455520 Phase 3 CG5503;placebo
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Impact of Lipoic Acid Use on Stroke Outcome After Reperfusion Therapy in Patients With Diabetes Recruiting NCT04041167 Phase 3 alpha lipoic acid;Saline
17 Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy Unknown status NCT00043797 Phase 2 Lidorestat (IDD 676)
18 Phase 2 Study of the NormaTec PCD in the Treatment of Diabetic Peripheral Neuropathy Unknown status NCT01175928 Phase 1, Phase 2
19 Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy Completed NCT01622777 Phase 2 Rosuvastatin;Placebo
20 A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy Completed NCT00878293 Phase 2 GRT6005;MS Continus®;Placebo
21 Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Completed NCT01607684 Phase 2
22 An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy Completed NCT00944697 Phase 2 Oxycodone Naloxone;Placebo tablets
23 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo Completed NCT01201317 Phase 2 AZD2423;AZD2423;Placebo
24 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
25 A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy Completed NCT00307749 Phase 2 Placebo;MCC-257;MCC-257;MCC-257
26 A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy. Completed NCT01347671 Phase 2 GRT6005;GRT6005;GRT6005;Matching Placebo
27 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
28 A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
29 A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT00507936 Phase 2 ABT-894;ABT-894;ABT-894;placebo;Duloxetine
30 A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy Completed NCT01079325 Phase 2 SB-509
31 A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity Completed NCT00476931 Phase 2
32 A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS) Completed NCT01849770 Phase 2 Mexiletine;Placebo
33 Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial Completed NCT02129231 Phase 2 calcined magnesia;Ezetimibe/simvastatin;Rosuvastatin
34 A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00406458 Phase 2 SB-509
35 A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509 Completed NCT00665145 Phase 2 SB-509;SB-509;Placebo;SB-509
36 A Phase IIa Dose Escalation Pilot Study to Investigate the Safety and Tolerability of Intranasal Insulin in Subjects With Diabetic Polyneuropathy. Completed NCT01469559 Phase 2 Novolin Toronto insulin;Normal saline
37 Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS) Completed NCT02781454 Phase 2 Mexiletine;Placebo
38 A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy Recruiting NCT03664921 Phase 2 Omnitram Oral Tablet;Placebo Oral Tablet
39 Nicotinamide Riboside in Diabetic Polyneuropathy Recruiting NCT03685253 Phase 1, Phase 2 Niagen;Placebo
40 ASP 8825 Phase II Study—A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy Terminated NCT00508430 Phase 2 ASP8825;Placebo
41 An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Terminated NCT00756041 Phase 2 TAK-128
42 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy Terminated NCT01087203 Phase 2
43 A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 150 mg and GLA5PR GLARS-NF3 Tablet 150 mg in Healthy Volunteers Completed NCT02955472 Phase 1 GLA5PR GLARS-NF3 tablet 150mg;GLA5PR GLARS-NF1 tablet 150mg
44 A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 300 mg and GLA5PR GLARS-NF3 Tablet 300 mg in Healthy Volunteers Completed NCT02952937 Phase 1 GLA5PR GLARS-NF3 tablet 300mg;GLA5PR GLARS-NF1 tablet 300mg
45 A Phase 1b, Randomized, Double-Blind, Parallel, Placebo- and Active-Controlled, Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy Not yet recruiting NCT04106050 Phase 1 BIIB095;BIIB074;Placebo;Lidocaine
46 Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain in Patients With Diabetic Polyneuropathy Using Proton MR Spectroscopy Unknown status NCT01180608
47 Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy Unknown status NCT01718015
48 Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy: a Multicenter Randomised Controlled Trial (PDP Study) Unknown status NCT01162993
49 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
50 Polyneuropathy in Diabetes Mellitus Type 2 Completed NCT02947828

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

Anatomical Context for Diabetic Polyneuropathy

MalaCards organs/tissues related to Diabetic Polyneuropathy:

40
Testes, Spinal Cord, Skin, Heart, Kidney, Pancreas, Endothelial

Publications for Diabetic Polyneuropathy

Articles related to Diabetic Polyneuropathy:

(show top 50) (show all 1102)
# Title Authors PMID Year
1
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. 54 61
17943821 2007
2
Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? 54 61
12198818 2002
3
[Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?]. 54 61
11433707 2001
4
Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. 54 61
11245210 2001
5
Biological actions of nerve growth factor in the peripheral nervous system. 54 61
10023124 1999
6
Neurotrophin-3 is increased in skin in human diabetic neuropathy. 54 61
9728960 1998
7
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]. 54 61
9789304 1998
8
The role of endogenous nerve growth factor in human diabetic neuropathy. 54 61
8640566 1996
9
Expressions of spinal microglia activation, BDNF, and DREAM proteins correlated with formalin-induced nociceptive responses in painful and painless diabetic neuropathy rats. 61
31902597 2020
10
Regional differences in cell-mediated immunity in people with diabetic peripheral neuropathy. 61
31557355 2020
11
Structural Nerve Remodeling at 3-T MR Neurography Differs between Painful and Painless Diabetic Polyneuropathy in Type 1 or 2 Diabetes. 61
31891321 2020
12
High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. 61
31904855 2020
13
Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord. 61
31334605 2020
14
Troponin T parallels Structural Nerve Damage in Type 2 Diabetes a Cross-sectional Study Using Magnetic Resonance Neurography. 61
31974140 2020
15
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats. 61
31794708 2020
16
Secreted factors from cultured dental pulp stem cells promoted neurite outgrowth of dorsal root ganglion neurons and ameliorated neural functions in streptozotocin-induced diabetic mice. 61
31144464 2020
17
Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. 61
31705717 2020
18
Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions. 61
31677343 2020
19
The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy. 61
31985124 2020
20
Diabetic polyneuropathy: Progress in diagnostic strategy and novel target discovery, but stagnation in drug development. 61
31755662 2020
21
Prospective Study of Neuropathic Symptoms Preceding Clinically Diagnosed Diabetic Polyneuropathy: ADDITION-Denmark. 61
31558545 2019
22
Microangiopathy: Is it relevant to wound healing in diabetic foot disease? 61
31845461 2019
23
Evaluation of spatio-temporal gait parameters and gait symmetry in diabetic polyneuropathic patients with burn injury: A pilot study. 61
31843285 2019
24
Understanding Diabetic Neuropathy: From Subclinical Nerve Lesions to Severe Nerve Fiber Deficits. A Cross-Sectional Study in Patients with Type 2 Diabetes and Healthy Controls. 61
31826867 2019
25
Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. 61
31788880 2019
26
Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. 61
31693539 2019
27
Early Detection of Diabetic Polyneuropathy Using Paired Stimulation Studies of the Sensory Nerves. 61
31136307 2019
28
Detection of early motor involvement in diabetic polyneuropathy using a novel MUNE method - MScanFit MUNE. 61
31476704 2019
29
The challenges of diabetic polyneuropathy: a brief update. 61
31306212 2019
30
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment. 61
31670029 2019
31
Impact of diabetic neuropathy severity on foot clearance complexity and variability during walking. 61
31550557 2019
32
What is normal trauma healing and what is complex regional pain syndrome I? An analysis of clinical and experimental biomarkers. 61
31095096 2019
33
Diabetes Mellitus Type Has Impact on Cutaneous Silent Period. 61
31819306 2019
34
Validity and reliability of a point-of-care nerve conduction device in diabetes patients. 61
30659760 2019
35
Painful and non-painful diabetic polyneuropathy: Clinical characteristics and diagnostic issues. 61
31222961 2019
36
Conditioned media from dental pulp stem cells improved diabetic polyneuropathy through anti-inflammatory, neuroprotective and angiogenic actions: Cell-free regenerative medicine for diabetic polyneuropathy. 61
30892819 2019
37
Dorsal Root Ganglion Stimulation in Experimental Painful Diabetic Polyneuropathy: Delayed Wash-Out of Pain Relief After Low-Frequency (1Hz) Stimulation. 61
31524325 2019
38
A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2 Splicesite Mutation and Concomitant Development of Non-diabetic Polyneuropathy 61
30563316 2019
39
Predictive Model of Diabetic Polyneuropathy Severity Based on Vitamin D Level. 61
31777620 2019
40
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. 61
31405030 2019
41
Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. 61
31314173 2019
42
painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. 61
30572741 2019
43
The fluctuation in sympathetic nerve activity around wake-up time was positively associated with not only morning but also daily glycemic variability in subjects with type 2 diabetes. 61
31078665 2019
44
Type of Diabetes Mellitus Has Influence on Electrophysiological Parameters. 61
31452568 2019
45
Association of Serum Cholesterol Levels With Peripheral Nerve Damage in Patients With Type 2 Diabetes. 61
31150078 2019
46
Effect of folic acid supplementation on nerve conduction velocity in diabetic polyneuropathy patients. 61
30730785 2019
47
Local infiltration anaesthesia versus sciatic nerve and adductor canal block for fast-track knee arthroplasty: A randomised controlled clinical trial. 61
30562225 2019
48
Effectiveness of dorsal root ganglion stimulation and dorsal column spinal cord stimulation in a model of experimental painful diabetic polyneuropathy. 61
30246327 2019
49
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan. 61
29975462 2019
50
The utility of a point-of-care sural nerve conduction device for detection of diabetic polyneuropathy: A cross-sectional study. 61
30582180 2019

Variations for Diabetic Polyneuropathy

Expression for Diabetic Polyneuropathy

Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for Diabetic Polyneuropathy

Pathways related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 VEGFA TNF NTF3 NOS3 NGF INS
2 12.68 VEGFA TNF NTF3 NGF INS
3
Show member pathways
12.32 NOS3 NOS2 NOS1 INS CYBA
4
Show member pathways
12.2 SLC25A4 NOS3 NOS2 NOS1
5
Show member pathways
12.16 NOS3 NOS2 NOS1 APOB
6
Show member pathways
12.1 TNF SOD3 SOD2 INS APOB
7 12.06 VEGFA TNF SLC25A4 NGF
8 11.95 VEGFA TNF NOS3 CYBA
9 11.8 VEGFA NOS3 NOS2 INS
10 11.71 VEGFA TNF NOS3 AGER
11 11.7 VEGFA NTF3 NGF
12
Show member pathways
11.59 VEGFA TNF NOS2
13
Show member pathways
11.55 NOS3 NOS2 NOS1
14
Show member pathways
11.52 NOS3 NOS2 NOS1
15
Show member pathways
11.49 SOD3 SOD2 CYBA
16 11.44 NOS3 NOS2 INS AGER
17 11.42 TNF APOB AGER
18
Show member pathways
11.34 NOS3 NOS2 NOS1
19
Show member pathways
11.3 NOS3 NOS2 NOS1
20 11.16 SOD3 SOD2 CYBA
21
Show member pathways
11.02 NOS3 NOS2 NOS1
22 10.7 NOS3 NOS2 NOS1 AKR1B1
23 10.55 NOS3 NOS2 NOS1
24 10.3 NOS3 NOS2 NOS1 CYBA
25 10.23 NOS3 NOS2 NOS1

GO Terms for Diabetic Polyneuropathy

Cellular components related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 VEGFA TNF SOD3 NTF3 NGF INS
2 cell GO:0005623 9.7 TWNK POLG NOS3 NOS2 NOS1 CYBA
3 Golgi lumen GO:0005796 9.5 SOD3 NGF INS
4 endosome lumen GO:0031904 9.13 NGF INS APOB
5 vesicle membrane GO:0012506 8.92 NOS3 NOS2 NOS1 APOB

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 10.04 SOD3 SOD2 NOS3 NOS2 NOS1 CYBA
2 positive regulation of gene expression GO:0010628 9.99 VEGFA TNF NOS3 NGF INS APOB
3 positive regulation of cell migration GO:0030335 9.92 VEGFA SOD2 NTF3 INS
4 response to lipopolysaccharide GO:0032496 9.87 NOS3 NOS2 NOS1 APOB
5 cellular response to oxidative stress GO:0034599 9.83 SOD3 SOD2 PARP1 CYBA
6 mitochondrion organization GO:0007005 9.82 TWNK PARP1 NOS3
7 response to organic substance GO:0010033 9.81 TNF APOB AKR1B1
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 TNF NTF3 INS
9 regulation of insulin secretion GO:0050796 9.78 TNF SLC25A4 NOS2
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 VEGFA TNF NTF3 NOS1
11 cellular response to glucose stimulus GO:0071333 9.77 TWNK POLG CYBA
12 response to hormone GO:0009725 9.76 NOS3 NOS2 NOS1
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TNF CYBA AKR1B1
14 cell redox homeostasis GO:0045454 9.73 NOS3 NOS2 NOS1 CYBA
15 negative regulation of blood pressure GO:0045776 9.71 NOS3 NOS2 NOS1
16 negative regulation of calcium ion transport GO:0051926 9.67 NOS3 NOS1
17 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.66 TNF AGER
18 nerve development GO:0021675 9.66 NTF3 NGF
19 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.65 SOD2 INS
20 regulation of protein secretion GO:0050708 9.65 TNF INS
21 nerve growth factor signaling pathway GO:0038180 9.65 NTF3 NGF
22 positive regulation of chemokine biosynthetic process GO:0045080 9.63 TNF AGER
23 nitric oxide mediated signal transduction GO:0007263 9.63 NOS3 NOS2 NOS1
24 negative regulation of potassium ion transport GO:0043267 9.62 NOS3 NOS1
25 mitochondrial DNA replication GO:0006264 9.61 TWNK POLG
26 negative regulation of hydrolase activity GO:0051346 9.59 NOS3 NOS1
27 induction of positive chemotaxis GO:0050930 9.58 VEGFA NTF3 AGER
28 peptidyl-cysteine S-nitrosylation GO:0018119 9.56 NOS2 NOS1
29 response to aldosterone GO:1904044 9.55 PARP1 CYBA
30 removal of superoxide radicals GO:0019430 9.54 SOD3 SOD2 NOS3
31 nitric oxide biosynthetic process GO:0006809 9.5 NOS3 NOS2 NOS1
32 positive regulation of guanylate cyclase activity GO:0031284 9.43 NOS3 NOS2 NOS1
33 arginine catabolic process GO:0006527 9.33 NOS3 NOS2 NOS1
34 superoxide metabolic process GO:0006801 9.26 SOD3 SOD2 NOS2 CYBA
35 response to hypoxia GO:0001666 9.1 VEGFA SOD3 NOS2 NOS1 CYBA AGER

Molecular functions related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.87 SOD3 SOD2 NOS3 NOS2 NOS1 CYBA
2 heme binding GO:0020037 9.73 NOS3 NOS2 NOS1 CYBA
3 protease binding GO:0002020 9.71 TWNK TNF POLG INS
4 flavin adenine dinucleotide binding GO:0050660 9.69 NOS3 NOS2 NOS1
5 NADP binding GO:0050661 9.63 NOS3 NOS2 NOS1
6 FMN binding GO:0010181 9.54 NOS3 NOS2 NOS1
7 cadmium ion binding GO:0046870 9.49 NOS3 NOS1
8 superoxide dismutase activity GO:0004784 9.48 SOD3 SOD2
9 arginine binding GO:0034618 9.43 NOS3 NOS2 NOS1
10 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS3 NOS2 NOS1
11 tetrahydrobiopterin binding GO:0034617 9.13 NOS3 NOS2 NOS1
12 nitric-oxide synthase activity GO:0004517 8.8 NOS3 NOS2 NOS1

Sources for Diabetic Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....